BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Summary

This phase IIa trial studies how well the experimental drug, BGJ398 (infigratinib), works in treating patients with fibroblast growth factor receptor (FGFR) 1-3 translocated, mutated, or amplified head and neck cancer that has returned after a period of improvement. BGJ398 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2018-06-01

Primary completion

2019-02-11

Completion

2019-02-11

Drugs

Indications